Enterobacter cloacae
Antibiotic |
% Susceptible 2010 |
% Susceptible 2012 |
% Susceptible 2014 |
% Susceptible 2016 |
% Susceptible 2018 |
Ampicillin | 4 |
0 | 0 | 0 | 0 |
Azithromycin | - |
- | - |
- | - |
Aztreonam | 82 |
83 | 87 |
85 | 85 |
Cefazolin | 1 |
0 | 0
0 |
0 |
|
Cefepime | + |
+ | +
+ |
+ |
|
Ceftazidime | 85 |
83 | 85 |
85 | 84 |
Ceftriaxone | 79 |
81 | 79 |
73 | 72 |
Cefuroxime | 5 |
0 | 0
0 |
0 |
|
Ciprofloxacin | 98 |
97 | 97 |
94 | 95 |
Clarithromycin | - |
- | - |
- | - |
Clindamycin | - |
- | - |
- | - |
Doxycycline | - |
89 | 89 |
+ | + |
Erythromycin | - |
- | - |
- | - |
Gentamicin | 98 |
98 | 98 |
96 | 97 |
Imipenem | 99 |
100 | 93 |
97 | 93 |
Levofloxacin | 98 | 98 | 99 | 98 | 97 |
Meropenem | + | 100 | 100 | 100 | 99 |
Moxifloxacin | + | + | + | + | + |
Nitrofurantoin | 28& | 28& | 29& | 31& | 34& |
Oxacillin/Naf | - | - | - | - | - |
Penicillin | - | - | - | - | - |
Piperacillin | 74 | 77 | 78 | + | + |
Piperacillin/tazo | 87 | 89 | 90 | 90 | 90 |
Ticarcillin/Clav | + | + | + | + | + |
Tobramycin | 98 | 98 | 98 | 96 | 97 |
TMP/SMX | 86 | 91 | 93 | 89 | 91 |
Unasyn/Aug | 7 | 0 | 0 | 0 | 0 |
Vancomycin | - | - | - | - | - |
# Tested | 190 | 289 | 239 | 274 | 268 |
Comments:
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections